Myeloproliferative Neoplasia (MPN) Genetic Panel in UAE | 2800 AED | DHA Licensed Molecular Diagnostics

Executive Summary & Core Metrics

✓

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing for JAK2, CALR, MPL, and BCR‑ABL1 driver mutations.

✓

Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.

✓

Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation by expert genetics consultants.

✓

Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.

Test Overview & Methodology

This next‑generation sequencing (NGS) panel simultaneously analyses four critical driver genes – JAK2 (V617F & exon 12), CALR (calreticulin), MPL (thrombopoietin receptor), and BCR‑ABL1 (quantitative) – enabling precise molecular diagnosis of Philadelphia chromosome‑negative myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, as well as BCR‑ABL1‑positive chronic myeloid leukaemia. The panel uses an Illumina‑based sequencing platform validated under ISO 9001:2015 and adheres to DHA diagnostic standards.

Feature	Our MPN Panel (NGS)	Sequential Single‑Gene Testing
Methodology	Illumina‑based Next‑Generation Sequencing (NGS)	PCR, Sanger sequencing (one gene at a time)
Genes Covered	JAK2, CALR, MPL, BCR‑ABL1 simultaneously	Typically one or two genes per order
Turnaround Time	15 working days	Cumulative 3–4 weeks if all genes tested
Diagnostic Sensitivity	>99.9% (ISO 9001:2015 validated)	Variable, risk of missing co‑mutations
Total Investment	2800 AED (package)	Often >3500 AED when performed separately

Physician Insight & Safety Protocols

“As a consultant in medical genetics, I emphasise that this NGS panel provides a comprehensive molecular profile of the key driver genes in myeloproliferative neoplasms. Results must be interpreted alongside complete blood counts, bone marrow morphology, and clinical presentation. A negative result does not entirely exclude all MPN subtypes, and ongoing haematological surveillance remains essential. Patients should integrate these findings into a personalised care plan under the guidance of their treating physician.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory & Safety Considerations

Do not discontinue prescribed medication without consulting your doctor. This test does not replace clinical surveillance.

• ER Red Flags: Seek emergency care if you experience sudden severe headache, visual disturbances, acute abdominal pain (possible thrombosis), fever >38.5°C, or unexplained bleeding or bruising.

Exclusion Criteria

⛔ Not for: Travel clearance, surgery clearance, or pregnancy/lactation screening.
⛔ Recent Transfusion: Do not perform the test if you had a blood transfusion within the last 2 weeks.
⛔ Minors: Legal guardian consent is required as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Patient FAQ & Clinical Guidance

1. What does the MPN panel test for?

Direct Answer: The MPN genetic panel detects mutations in JAK2 (V617F & exon 12), CALR, MPL, and BCR‑ABL1 genes using Next‑Generation Sequencing, providing a comprehensive molecular diagnosis for myeloproliferative neoplasms.

2. How long does it take to receive the test result?

Direct Answer: Results are typically available within 15 working days from sample collection and are delivered securely via our DHA‑compliant encrypted portal.

3. Is a doctor’s prescription required for this test?

Direct Answer: A valid doctor’s prescription is mandatory; however, this test is not applicable for surgery clearance, pregnancy cases, or travel abroad, as per UAE healthcare regulations.

4. Can home collection be arranged for this test?

Direct Answer: Yes. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection is available daily from 8 AM to 11 PM. A valid prescription is required at the time of collection.

UAE Regulatory & Data Privacy Adherence

All clinical and genetic data are processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient results are delivered exclusively through encrypted portals, and no genetic information is shared without explicit consent. The laboratory holds DHA Facility License No. 1143 and follows ISO 9001:2015 quality management standards.

Clinical & Logistical Metadata

Test Name	Myeloproliferative Neoplasia (MPN) Genetic Panel
Price (AED)	2800 AED
Turnaround Time	15 working days
Sample Type / Matrix	Peripheral Whole Blood
Methodology Used	Next‑Generation Sequencing (NGS) – Illumina Platform
ICD‑10‑CM Code	D47.1, D45, C92.1, D47.4
LOINC Code	92489-1
DHA Facility License & Laboratory Address	DHA License 1143 \| DNA Labs UAE \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE